Hostname: page-component-76fb5796d-vfjqv Total loading time: 0 Render date: 2024-04-27T16:42:20.024Z Has data issue: false hasContentIssue false
  • English
  • Français

Vitamin D3 and its Potential to Ameliorate Chemical and Radiation-Induced Skin Injury During Cancer Therapy

Published online by Cambridge University Press:  15 January 2024

Cuong V. Nguyen  and
Kurt Q. Lu Open the ORCID record for Kurt Q. Lu [Opens in a new window]
Cuong V. Nguyen
Affiliation:
Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
Kurt Q. Lu*
Affiliation:
Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
*
Corresponding author: Kurt Q. Lu; Email: Kurt.Lu@northwestern.edu.
Rights & Permissions [Opens in a new window]

Abstract

Skin injury and dermatitis are common complications following chemotherapy and radiation administration for cancer treatment. Symptomatic relief of these complications is limited to slow-acting therapies and often results in holding or modifying cancer therapy that may impact patient outcomes. The off-label use of oral high dose vitamin D3 has demonstrated rapid clinical improvement in skin inflammation and swelling in both chemotherapy and radiation-induced injury. Furthermore, vitamin D3 has been shown to downregulate pro-inflammatory pathways and cytokines, including NFkB, and CCL2, as well as CCL20, which are not only involved in tissue injury, but may confer resistance to cancer treatment. In this paper, we discuss 2 patients with acute radiation dermatitis and acute radiation recall dermatitis following chemotherapy who received 50 000 – 100 000 IU of oral high dose vitamin D3 with improvement in their symptoms. These findings may indicate the potential use of vitamin D as a therapeutic intervention and future target for studying skin healing following chemotherapy and/ or radiation-induced cutaneous toxicity.

Keywords

toxic erythema of chemotherapyradiation dermatitisvitamin Dsupportive oncodermatologyskin injury
Type
Brief Report
Information
Disaster Medicine and Public Health Preparedness , Volume 18 , 2024 , e4
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of Society for Disaster Medicine and Public Health, Inc

Background

The American Cancer Society estimated that approximately 1.96 million new cases of cancer will be diagnosed, in 2023. 1 Unfortunately, during oncologic treatment with chemo- and radiation therapy, patients may develop skin injury with potential progression to blistering, and ulceration, as well as necrosis. High grade reactions occur in 25% to approximately 50% of patients receiving chemotherapy or radiation, respectively. Reference Miller, Gorcey and McLellan2,Reference Yee, Wang and Asthana3 Despite the relatively common occurrence of these cutaneous adverse events, there are no standard therapeutic regimens to alleviate symptoms. Modification, cessation, or delay of the patient’s cancer management are the most reliable methods to resolve skin injury. Yet, even after stopping chemotherapy, skin injuries may take 2 - 4 weeks to heal even with the addition of high-potency topical steroids, and pain control, as well as proper wound care. However, such alterations in oncologic treatment may negatively impact patient survival and outcomes. As such, further study of additional treatment modalities for the acute management of chemo- and radiation-induced skin injury are needed.

More recently, vitamin D has emerged as a critical immunomodulatory hormone, which has well-established regulatory properties for both the innate and adaptive immune systems, promoting inflammatory control by suppression of hallmark inflammatory factors. Reference Ernst, Evans and Techner4

Of note, high-dose vitamin D3 (hdvD) has demonstrated accelerated resolution of UV-induced skin injury in patients with acute sunburns, improved chemical-induced wounds in animal and human trials following topical nitrogen mustard exposure, and rapidly mitigated toxic injury from chemotherapy in hospitalized patients. Reference Ernst, Evans and Techner4–Reference Nguyen, Zheng and Zhou6 In addition, it was recently observed in a retrospective case series that hdvD rapidly leads to symptomatic relief in patients with acute radiation dermatitis. Reference Nguyen, Zheng and Lu7

Toxic skin injury from chemotherapy and radiation may demonstrate overlapping pathogenic mechanisms. Further understanding of how this occurs can help improve the quality of life in patients undergoing cancer treatment. Here, we present 2 patient cases that illustrate this potential intersection between chemotherapy and radiation associated skin injury and their improvement with oral hdvD.

Methods

A retrospective review was performed in 2 adult patients who received oral hdvD for acute radiation dermatitis or acute radiation recall dermatitis following chemotherapy administration. Oncologic history and clinical characteristics were abstracted from electronic health records, following the American Journal of Ophthalmology reporting guideline. This case series did not require approval based on the requirements by the Northwestern University Institutional Review Board, and the informed consent requirement was waived because de-identified data were used.

Results

Two female patients with a history of breast cancer were evaluated for acute radiation dermatitis, the second of which developed radiation recall dermatitis 1 week following administration of navelbine (clinical features summarized in Table 1). Both patients received 50 000 – 100 000 IU of oral ergocalciferol once with a repeat dose 1 week later. Patient 1 with acute radiation dermatitis required systemic and topical steroids along with oral opiates for pain control prior to the addition of hdvD. Following intervention with hdvD, she had significant subjective improvement in pain and swelling within 3 - 7 days that had not improved with her prior therapies. The patient is currently alive and in disease remission. Patient 2 also had improvement in her acute symptoms of swelling and burning pain, but due to carcinoma en cuirasse of the left breast skin, she continued to have induration and developed skin ulceration with fibrinous and necrotic crusting. She ultimately developed further systemic metastases and passed away from disease progression. See Figure 1 for representative clinical images.

Table 1. Clinical characteristics of patients

Figure 1. A. Patient 1. Bright red erythema of the chest wall prior to hdvD. B. Patient 1. Near complete resolution of erythema and swelling 7 days after hdvD. C. Patient 2. Superficial ulcer of the left breast with well-demarcated erythema extending to the right chest wall prior to hdvD. D. Patient 2. Improvement in erythema and swelling of 14 days following hdvD, but with continued ulceration in the setting of carcinoma en cuirasse.

Discussion

Vitamin D3 is an immunomodulating hormone that plays a vital role in the innate and adaptive immune system. The administration of vitamin D3 leads to improvement in epidermal regeneration and inflammatory suppression via inhibition of pro-inflammatory NFkB, signaling and up-regulation of arginase- 1, an anti-inflammatory tissue repair factor found in macrophages. Reference Ernst, Evans and Techner4

Monocytes and tissue macrophages are important regulators of tissue injury, especially in the setting of chemotherapy and radiation treatment. Systemic chemotherapy is thought to affect the skin via secretion by eccrine glands with direct toxic effect on the skin. Reference Miller, Gorcey and McLellan2 In mouse and human trials, exposure to topical nitrogen mustard results in inflamed skin and up-regulation of CCL2 and CCL20, markers important in monocytic differentiation, and as a chemo-attractant for immature dendritic cells and T-cells, respectively. Reference Ernst, Evans and Techner4 Similarly, these inflammatory markers may be activated in the setting of radiation treatment with up-regulation of CCL2 in normal tissue following radiation producing skin damage. Reference Wang, Jiang and Chen8 The activation of the NFkB signaling pathway is important in the regulation of these pro-inflammatory cytokines, and as such, downregulation by vitamin D3 may help explain the benefit of this intervention in treating chemotherapy and radiation-induced cutaneous toxicity.

Interestingly, the upregulation of CCL2 and CCL20 may result in increased cancer resistance to radiation treatment and chemotherapy. Reference Wang, Jiang and Chen8,Reference Geismann, Grohmann and Dreher9 In addition to improving skin-related symptoms, downregulation of CCL2 and CCL20 may also help improve cancer response to treatment, but further research is needed to confirm this hypothesis. However, additional data to support this theory may not be far off. A randomized controlled trial is currently pending to evaluate the role of monthly hdvD at doses of 50 000 IU in patients with prostate cancer to determine its role in cancer progression prevention. Reference Nair-Shalliker, Smith and Gebski10

It is important to note that the administration of oral hdvD appears to be safe. In a meta-analysis of 7 clinical trials that included 716 critically-ill patients, administration of single vitamin D doses ranging from 200 000 – 600 000 IU demonstrated no significant adverse events, especially in calcium levels or renal function. Reference Putzu, Belletti and Cassina11 In fact, patients in the hdvD group demonstrated a significant reduction in mortality compared to placebo. There also did not appear to be an effect on length of hospital stays, length of intensive care unit stays, or length of mechanical ventilation. Information on the effects of hdvD on treatment related side effects were not documented in these studies.

Given the shared pro-inflammatory cytokine pathway involved in both chemotherapy and radiation-induced dermatitis, it is likely that these 2 processes occur by similar mechanisms. The development of radiation recall dermatitis following chemotherapy administration and the improvement of both patients in this study with oral hdvD further demonstrates that there is some overlap between these 2 conditions. However, as radiation therapy creates deeper dermal skin injury, it may require higher doses of vitamin D3 to provide similar benefits. Study limitations include the small cohort size, retrospective nature, and lack of long-term follow-up. As chemotherapy and radiation associated dermatitis may significantly impact the quality of life and treatment of cancer patients, it is imperative that future investigations evaluate the pathways by which these conditions occur. High dose vitamin D3 intervention may provide such a model to both explore pathogenic mechanisms and translate into a safe intervention for patient care.

Author contributions

Cuong V. Nguyen drafted the initial manuscript. Kurt Q. Lu provided critical revisions. Both authors had complete access to the data. Kurt Q. Lu also takes responsibility for the integrity of the data and the accuracy of the data analysis.

Funding statement

No funding or sponsorship was received for any aspect of this article, including design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

Competing interests

All authors report no conflicts of interest.

References

American Cancer Society. Cancer facts and figures 2023. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf. Accessed June 24, 2023.Google Scholar
Miller, KK, Gorcey, L, McLellan, BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 2014;71(4):787-794.CrossRefGoogle ScholarPubMed
Yee, C, Wang, K, Asthana, R, et al. Radiation-induced skin toxicity in breast cancer patients: a systematic review of randomized trials. Clin Breast Cancer. 2018;18(5):e825-e840.CrossRefGoogle ScholarPubMed
Ernst, MK, Evans, ST, Techner, J-M, et al. Vitamin D3 and deconvoluting a rash. JCI insight. 2023;8(2).CrossRefGoogle ScholarPubMed
Scott, JF, Das, LM, Ahsanuddin, S, et al. Oral Vitamin D rapidly attenuates inflammation from sunburn: an interventional study. J Invest Dermatol. 2017;137(10):2078-2086.CrossRefGoogle ScholarPubMed
Nguyen, CV, Zheng, L, Zhou, XA, et al. High-dose Vitamin D for the management of toxic erythema of chemotherapy in hospitalized patients. JAMA Dermatology. 2023;159(2):219.CrossRefGoogle ScholarPubMed
Nguyen, CV, Zheng, L, Lu, KQ. High-dose vitamin D for the management acute radiation dermatitis. JAAD case reports. 2023;39:47-50.CrossRefGoogle ScholarPubMed
Wang, L, Jiang, J, Chen, Y, et al. The roles of CC chemokines in response to radiation. Radiat Oncol. 2022;17(1):63.CrossRefGoogle ScholarPubMed
Geismann, C, Grohmann, F, Dreher, A, et al. Role of CCL20 mediated immune cell recruitment in NF-κB mediated TRAIL resistance of pancreatic cancer. Biochim Biophys acta Mol cell Res. 2017;1864(5):782-796.CrossRefGoogle ScholarPubMed
Nair-Shalliker, V, Smith, DP, Gebski, V, et al. High-dose vitamin D supplementation to prevent prostate cancer progression in localized cases with low-to-intermediate risk of progression on active surveillance (ProsD): protocol of a phase II randomized controlled trial. BMJ Open. 2021;11(3):e044055.CrossRefGoogle Scholar
Putzu, A, Belletti, A, Cassina, T, et al. Vitamin D and outcomes in adult critically ill patients. A systematic review and meta-analysis of randomized trials. J Crit Care. 2017;38:109-114.CrossRefGoogle ScholarPubMed
Figure 0

Table 1. Clinical characteristics of patients

Figure 1

Figure 1. A. Patient 1. Bright red erythema of the chest wall prior to hdvD. B. Patient 1. Near complete resolution of erythema and swelling 7 days after hdvD. C. Patient 2. Superficial ulcer of the left breast with well-demarcated erythema extending to the right chest wall prior to hdvD. D. Patient 2. Improvement in erythema and swelling of 14 days following hdvD, but with continued ulceration in the setting of carcinoma en cuirasse.